Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00885742 · ClinicalTrials.gov registry record · Phase 3
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Phase 3 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT00885742 is a Phase 3 study that has completed, run by CSL Behring. The registered enrollment target is 41 participants.
The verdict
NCT00885742, a Phase 3 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
Congenital deficiency of factor XIII (FXIII) is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII. Factor XIII Concentrate works by assisting blood in the usual clotting process, thereby preventing bleeding. In this study, patients will be treated with FXIII Concentrate (Human) and followed closely to determine that they receive the dose that will best minimize the chance of bruising and bleeding.
Interventions
- BIOLOGICAL FXIII Concentrate (Human)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00885742
The ClinicalTrials.gov registry entry for NCT00885742 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FXIII Concentrate (Human) is the first listed.
NCT00885742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00885742 about?
NCT00885742 is a clinical study titled "A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency". Congenital deficiency of factor XIII (FXIII) is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII. Factor XIII Concentrate works by assisting blood in the usual clotting process,...
What is the current status of trial NCT00885742?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2009-08. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00885742?
The interventions under investigation include: FXIII Concentrate (Human) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00885742?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.